RE:RE:RE:RE:RE:RE:RE:ONCY has just added to the profit margin of Cantor FitzgeralThe average estimated total cost for all "per patient'' activities of a clinical trial with new anticancer agents was 11,379 Euros / US$12,421 per patient using the activity-based costing (ABC) methodology.
Pivotal (phase 3) studies for new drugs that were subsequently approved by the U.S. Food and Drug Administration (FDA) cost a median of $41,117 per patient.